trends

This morning, Helicore Biopharma emerged from stealth with $65M in Series A funding. They are focused on the discovery and development of first-in-class glucose-dependent insulinotropic peptide (GIP) antagonists, with their most advanced asset, HCR-188, being a clinical stage monoclonal antibody (mAb) designed to bind GIP.

A common theme emerging from recent antibody research is the development and validation of advanced diagnostic tools based on antibody detection. Multiple studies highlight the creation of novel biosensors and assays designed to enhance the sensitivity, specificity, and efficiency of detecting antibodies across various diseases.

These past few weeks, several antibody drug startups have progressed from the pre-seed stage to final funding rounds. In the pre-seed stage, the focus is on early research, often funded by founders, grants, or angel investors. As the company progresses to the seed stage, it seeks additional funding to validate its scientific concept and develop initial prototypes, attracting early-stage venture capital.

Over four years have passed since the first SARS-CoV-2 outbreak, and scientific advancements have reshaped our understanding of immunity and virus dynamics.